| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 4 | 2026 | 1110 | 0.530 |
Why?
|
| Community Pharmacy Services | 1 | 2016 | 6 | 0.500 |
Why?
|
| Community Health Planning | 1 | 2016 | 23 | 0.500 |
Why?
|
| Professional Role | 1 | 2016 | 40 | 0.490 |
Why?
|
| Precision Medicine | 3 | 2021 | 502 | 0.450 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 72 | 0.410 |
Why?
|
| Patient Care Team | 1 | 2016 | 318 | 0.400 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 473 | 0.370 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 22 | 0.370 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2012 | 42 | 0.360 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 44 | 0.360 |
Why?
|
| Haplotypes | 1 | 2014 | 657 | 0.360 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2012 | 406 | 0.350 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 2381 | 0.340 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 3032 | 0.320 |
Why?
|
| Neoplasms | 9 | 2023 | 3349 | 0.320 |
Why?
|
| Adenoma | 1 | 2012 | 262 | 0.310 |
Why?
|
| Skin Neoplasms | 7 | 2013 | 638 | 0.290 |
Why?
|
| Breast Neoplasms | 19 | 2013 | 3285 | 0.250 |
Why?
|
| Thiophenes | 1 | 2026 | 46 | 0.230 |
Why?
|
| Quinazolines | 2 | 2026 | 221 | 0.230 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1775 | 0.230 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 154 | 0.230 |
Why?
|
| Humans | 76 | 2026 | 98370 | 0.210 |
Why?
|
| Mutation | 3 | 2023 | 4428 | 0.200 |
Why?
|
| Aged | 42 | 2026 | 21844 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 402 | 0.190 |
Why?
|
| Middle Aged | 48 | 2026 | 29532 | 0.190 |
Why?
|
| Female | 54 | 2026 | 51761 | 0.180 |
Why?
|
| Dietary Fats | 4 | 2009 | 135 | 0.180 |
Why?
|
| Prostatic Neoplasms | 6 | 2016 | 1842 | 0.180 |
Why?
|
| Postmenopause | 7 | 2013 | 109 | 0.180 |
Why?
|
| ErbB Receptors | 1 | 2005 | 517 | 0.170 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 22 | 0.170 |
Why?
|
| Outpatients | 1 | 2021 | 106 | 0.170 |
Why?
|
| Viral Load | 1 | 2021 | 162 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 177 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 82 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 889 | 0.160 |
Why?
|
| Thrombosis | 1 | 2023 | 318 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 639 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 118 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 341 | 0.150 |
Why?
|
| Patient Care Planning | 2 | 2021 | 92 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 1419 | 0.140 |
Why?
|
| Male | 35 | 2026 | 47263 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2015 | 1539 | 0.130 |
Why?
|
| Isotretinoin | 1 | 2017 | 22 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 578 | 0.130 |
Why?
|
| Ovarian Neoplasms | 5 | 2007 | 828 | 0.130 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 391 | 0.130 |
Why?
|
| Molecular Biology | 1 | 1997 | 83 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2021 | 606 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 923 | 0.120 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 419 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 65 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 2017 | 80 | 0.120 |
Why?
|
| Carcinoma | 3 | 1995 | 442 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 1997 | 225 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 178 | 0.110 |
Why?
|
| Aftercare | 1 | 1996 | 92 | 0.110 |
Why?
|
| Cisplatin | 2 | 1990 | 578 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 222 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 1107 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 244 | 0.110 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1995 | 15 | 0.110 |
Why?
|
| Pleura | 1 | 1995 | 31 | 0.110 |
Why?
|
| Melanoma | 2 | 2012 | 524 | 0.110 |
Why?
|
| Prospective Studies | 10 | 2023 | 4818 | 0.110 |
Why?
|
| Self Care | 1 | 2015 | 188 | 0.100 |
Why?
|
| Health Promotion | 1 | 2015 | 176 | 0.100 |
Why?
|
| Dysgerminoma | 1 | 1993 | 7 | 0.100 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 1993 | 39 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 402 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 2 | 2012 | 155 | 0.090 |
Why?
|
| Malpractice | 1 | 1993 | 47 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 233 | 0.090 |
Why?
|
| Adult | 26 | 2026 | 29587 | 0.090 |
Why?
|
| Risk | 3 | 2011 | 660 | 0.090 |
Why?
|
| Adenocarcinoma | 9 | 1994 | 1214 | 0.090 |
Why?
|
| Risk Factors | 7 | 2023 | 6273 | 0.090 |
Why?
|
| Anthropometry | 1 | 2011 | 77 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 2 | 2017 | 1088 | 0.080 |
Why?
|
| Breast | 3 | 2010 | 316 | 0.080 |
Why?
|
| Demography | 1 | 2011 | 193 | 0.080 |
Why?
|
| Total Quality Management | 1 | 2011 | 31 | 0.080 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 162 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 360 | 0.080 |
Why?
|
| Lip Neoplasms | 1 | 1990 | 10 | 0.080 |
Why?
|
| Mass Screening | 1 | 1996 | 751 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2004 | 100 | 0.080 |
Why?
|
| Time Factors | 6 | 2013 | 5577 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1993 | 403 | 0.080 |
Why?
|
| Amygdalin | 2 | 1980 | 3 | 0.080 |
Why?
|
| Linoleic Acid | 1 | 2009 | 5 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 1945 | 0.080 |
Why?
|
| Arachidonic Acid | 1 | 2009 | 63 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2012 | 450 | 0.080 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2009 | 22 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 440 | 0.080 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 231 | 0.070 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 132 | 0.070 |
Why?
|
| Docosahexaenoic Acids | 1 | 2009 | 35 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 109 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 71 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2007 | 2661 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2012 | 663 | 0.070 |
Why?
|
| Fluorouracil | 4 | 2026 | 543 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2012 | 528 | 0.070 |
Why?
|
| United States | 5 | 2017 | 8262 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 24 | 0.070 |
Why?
|
| Drug Evaluation | 13 | 1989 | 109 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2007 | 771 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 48 | 0.060 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2001 | 96 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 1268 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2010 | 449 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2021 | 726 | 0.060 |
Why?
|
| Internal Medicine | 2 | 2011 | 337 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 682 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2026 | 15 | 0.060 |
Why?
|
| Teniposide | 2 | 1986 | 6 | 0.060 |
Why?
|
| Podophyllotoxin | 2 | 1986 | 9 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 553 | 0.060 |
Why?
|
| Urologic Neoplasms | 2 | 1989 | 82 | 0.060 |
Why?
|
| Women's Health | 3 | 2013 | 120 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2001 | 111 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2574 | 0.060 |
Why?
|
| Work Schedule Tolerance | 1 | 2005 | 34 | 0.060 |
Why?
|
| Neoplasm Metastasis | 10 | 2007 | 1094 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 755 | 0.060 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 4044 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 1133 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 1989 | 158 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 2085 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 356 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2010 | 1721 | 0.050 |
Why?
|
| Biomarkers | 1 | 2012 | 2021 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2007 | 352 | 0.050 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2005 | 103 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 242 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2009 | 583 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 7418 | 0.050 |
Why?
|
| Progesterone Congeners | 1 | 2003 | 4 | 0.050 |
Why?
|
| Factor V | 1 | 2023 | 9 | 0.050 |
Why?
|
| Liver Neoplasms | 3 | 2007 | 826 | 0.050 |
Why?
|
| Prothrombin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2003 | 16 | 0.050 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2003 | 23 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 52 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 446 | 0.050 |
Why?
|
| Diethylstilbestrol | 2 | 1985 | 121 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1785 | 0.050 |
Why?
|
| Reminder Systems | 2 | 2012 | 19 | 0.040 |
Why?
|
| Preexisting Condition Coverage | 1 | 2021 | 3 | 0.040 |
Why?
|
| Hemangiosarcoma | 1 | 2001 | 16 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 1982 | 114 | 0.040 |
Why?
|
| Menogaril | 1 | 2001 | 3 | 0.040 |
Why?
|
| Population | 1 | 2021 | 36 | 0.040 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 21 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2012 | 9770 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2001 | 35 | 0.040 |
Why?
|
| Thiadiazoles | 2 | 1994 | 14 | 0.040 |
Why?
|
| Neutropenia | 1 | 2021 | 211 | 0.040 |
Why?
|
| Prognosis | 5 | 2017 | 4126 | 0.040 |
Why?
|
| United Kingdom | 1 | 2021 | 212 | 0.040 |
Why?
|
| Rectal Neoplasms | 3 | 1987 | 138 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 194 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2016 | 1529 | 0.040 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2010 | 32 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 1979 | 28 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2021 | 176 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2010 | 42 | 0.040 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1979 | 16 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 554 | 0.040 |
Why?
|
| Semustine | 1 | 1979 | 2 | 0.040 |
Why?
|
| Nitrosourea Compounds | 1 | 1979 | 9 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 1979 | 36 | 0.040 |
Why?
|
| Glucagon | 1 | 1979 | 114 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 1979 | 15 | 0.040 |
Why?
|
| Mammography | 1 | 2003 | 504 | 0.040 |
Why?
|
| Glioblastoma | 2 | 1996 | 300 | 0.040 |
Why?
|
| Incidence | 3 | 2012 | 1787 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 1996 | 525 | 0.040 |
Why?
|
| Nipples | 1 | 1979 | 40 | 0.040 |
Why?
|
| Methylation | 2 | 2010 | 294 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 325 | 0.040 |
Why?
|
| Combined Modality Therapy | 6 | 1996 | 1752 | 0.040 |
Why?
|
| Heat-Shock Proteins | 1 | 1999 | 178 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2010 | 529 | 0.030 |
Why?
|
| Histones | 2 | 2010 | 364 | 0.030 |
Why?
|
| Physical Examination | 3 | 1996 | 149 | 0.030 |
Why?
|
| Carcinoma 256, Walker | 2 | 1979 | 4 | 0.030 |
Why?
|
| Animals | 4 | 2014 | 28981 | 0.030 |
Why?
|
| Colonic Neoplasms | 3 | 1987 | 588 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 272 | 0.030 |
Why?
|
| Time | 1 | 1977 | 80 | 0.030 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1977 | 28 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1978 | 135 | 0.030 |
Why?
|
| Paclitaxel | 1 | 1998 | 484 | 0.030 |
Why?
|
| Mesothelioma | 2 | 1995 | 346 | 0.030 |
Why?
|
| Benzoquinones | 2 | 1987 | 27 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1996 | 81 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 2 | 1987 | 44 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2021 | 11043 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2005 | 1126 | 0.030 |
Why?
|
| Brain Neoplasms | 3 | 1996 | 843 | 0.030 |
Why?
|
| Gene Expression | 1 | 1999 | 1322 | 0.030 |
Why?
|
| Transitional Care | 1 | 2015 | 26 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 425 | 0.030 |
Why?
|
| Thoracotomy | 1 | 1995 | 71 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1996 | 259 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 1998 | 372 | 0.030 |
Why?
|
| Drainage | 1 | 1995 | 176 | 0.030 |
Why?
|
| Survival Rate | 2 | 1996 | 2050 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 211 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 202 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 2896 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 1978 | 289 | 0.020 |
Why?
|
| New Jersey | 1 | 1993 | 7 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 180 | 0.020 |
Why?
|
| Sunlight | 1 | 2013 | 27 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2007 | 1947 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1790 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 917 | 0.020 |
Why?
|
| Radioisotope Teletherapy | 1 | 1992 | 4 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1992 | 6 | 0.020 |
Why?
|
| Cobalt Radioisotopes | 1 | 1992 | 19 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2012 | 42 | 0.020 |
Why?
|
| Reimbursement, Incentive | 1 | 2012 | 37 | 0.020 |
Why?
|
| Zoxazolamine | 1 | 1972 | 2 | 0.020 |
Why?
|
| Hexobarbital | 1 | 1972 | 2 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 99 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2012 | 7 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 1972 | 48 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2012 | 2599 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 2009 | 0.020 |
Why?
|
| Feedback | 1 | 2012 | 132 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1993 | 245 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2012 | 51 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 112 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1974 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2012 | 58 | 0.020 |
Why?
|
| Phosphoric Acids | 1 | 1971 | 5 | 0.020 |
Why?
|
| Troponin I | 1 | 2012 | 27 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 1993 | 520 | 0.020 |
Why?
|
| Myocardium | 2 | 2012 | 578 | 0.020 |
Why?
|
| Insecticides | 1 | 1971 | 26 | 0.020 |
Why?
|
| Complement Activation | 1 | 2012 | 88 | 0.020 |
Why?
|
| Recurrence | 1 | 1995 | 1264 | 0.020 |
Why?
|
| Cyclophosphamide | 4 | 1992 | 284 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 1983 | 765 | 0.020 |
Why?
|
| Drug Administration Schedule | 3 | 1998 | 837 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 373 | 0.020 |
Why?
|
| Vitamin D | 1 | 2013 | 286 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 194 | 0.020 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2010 | 10 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 1972 | 258 | 0.020 |
Why?
|
| Mitoguazone | 1 | 1989 | 2 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2010 | 80 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Documentation | 1 | 2011 | 112 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 23 | 0.020 |
Why?
|
| Vinblastine | 1 | 1989 | 84 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 156 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 426 | 0.020 |
Why?
|
| Oxazoles | 1 | 1989 | 14 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2011 | 227 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 112 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 111 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 160 | 0.020 |
Why?
|
| Aziridines | 2 | 1987 | 10 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 159 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 345 | 0.020 |
Why?
|
| Isoxazoles | 1 | 1989 | 81 | 0.020 |
Why?
|
| Lysine | 1 | 2010 | 170 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1993 | 1570 | 0.020 |
Why?
|
| Clinical Trials as Topic | 6 | 1987 | 1126 | 0.020 |
Why?
|
| Leukopenia | 3 | 1985 | 66 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 396 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 190 | 0.020 |
Why?
|
| Kidney Neoplasms | 2 | 1985 | 556 | 0.020 |
Why?
|
| Thyroid Neoplasms | 2 | 1986 | 469 | 0.020 |
Why?
|
| Edible Grain | 1 | 2007 | 9 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 876 | 0.020 |
Why?
|
| Vegetables | 1 | 2007 | 50 | 0.020 |
Why?
|
| Fruit | 1 | 2007 | 82 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 403 | 0.020 |
Why?
|
| Liver | 1 | 1972 | 1230 | 0.020 |
Why?
|
| Acid Phosphatase | 2 | 1985 | 28 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 69 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2007 | 60 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1296 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1987 | 87 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2007 | 218 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2010 | 710 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 3228 | 0.010 |
Why?
|
| Chicago | 1 | 2011 | 1519 | 0.010 |
Why?
|
| Medulloblastoma | 1 | 1986 | 44 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2007 | 246 | 0.010 |
Why?
|
| Azirines | 1 | 1985 | 3 | 0.010 |
Why?
|
| Lung Neoplasms | 4 | 1995 | 2471 | 0.010 |
Why?
|
| Weight Loss | 1 | 2007 | 245 | 0.010 |
Why?
|
| Radio Waves | 1 | 1985 | 20 | 0.010 |
Why?
|
| Germanium | 1 | 1984 | 4 | 0.010 |
Why?
|
| Medical Errors | 1 | 2005 | 93 | 0.010 |
Why?
|
| Anthraquinones | 1 | 1984 | 9 | 0.010 |
Why?
|
| Job Satisfaction | 1 | 2005 | 86 | 0.010 |
Why?
|
| Spiro Compounds | 1 | 1984 | 24 | 0.010 |
Why?
|
| Mitolactol | 1 | 1984 | 1 | 0.010 |
Why?
|
| Workload | 1 | 2005 | 130 | 0.010 |
Why?
|
| Sleep Deprivation | 1 | 2005 | 128 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 187 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1985 | 77 | 0.010 |
Why?
|
| BCG Vaccine | 2 | 1984 | 44 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1397 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1752 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 813 | 0.010 |
Why?
|
| Burnout, Professional | 1 | 2005 | 125 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1984 | 142 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1985 | 170 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1984 | 177 | 0.010 |
Why?
|
| Mastectomy | 3 | 1980 | 273 | 0.010 |
Why?
|
| Thyroxine | 1 | 1986 | 411 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1983 | 244 | 0.010 |
Why?
|
| Indomethacin | 1 | 1983 | 58 | 0.010 |
Why?
|
| Glioma | 1 | 1985 | 309 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 578 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 7568 | 0.010 |
Why?
|
| Interferons | 1 | 1983 | 114 | 0.010 |
Why?
|
| Radiotherapy | 2 | 1986 | 325 | 0.010 |
Why?
|
| Carmustine | 2 | 1996 | 70 | 0.010 |
Why?
|
| Attitude | 1 | 1983 | 133 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1982 | 54 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1982 | 90 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1982 | 239 | 0.010 |
Why?
|
| Energy Intake | 2 | 1993 | 100 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1982 | 85 | 0.010 |
Why?
|
| Monocytes | 1 | 1983 | 220 | 0.010 |
Why?
|
| Syndrome | 1 | 1982 | 442 | 0.010 |
Why?
|
| Depression | 1 | 2005 | 619 | 0.010 |
Why?
|
| Random Allocation | 3 | 1986 | 312 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2001 | 115 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 2688 | 0.010 |
Why?
|
| Pleural Neoplasms | 1 | 1982 | 207 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1980 | 111 | 0.010 |
Why?
|
| Rodentia | 1 | 1980 | 49 | 0.010 |
Why?
|
| Heart Failure | 1 | 2011 | 1502 | 0.010 |
Why?
|
| Streptozocin | 1 | 1979 | 56 | 0.010 |
Why?
|
| Rats | 2 | 1979 | 4074 | 0.010 |
Why?
|
| Lymphedema | 1 | 2001 | 91 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1979 | 45 | 0.010 |
Why?
|
| Cyanides | 1 | 1979 | 16 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1979 | 59 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1979 | 83 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1989 | 403 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 530 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1979 | 112 | 0.010 |
Why?
|
| Physicians | 1 | 2005 | 685 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1998 | 158 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1992 | 285 | 0.010 |
Why?
|
| Skin | 1 | 2001 | 591 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1979 | 397 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1979 | 421 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 2056 | 0.010 |
Why?
|
| Adolescent | 4 | 1987 | 10140 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1977 | 13 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 1899 | 0.010 |
Why?
|
| Bone Neoplasms | 3 | 1985 | 316 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1977 | 66 | 0.010 |
Why?
|
| Mitomycin | 1 | 1996 | 30 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 1996 | 43 | 0.010 |
Why?
|
| Mercaptopurine | 1 | 1996 | 53 | 0.010 |
Why?
|
| Cell Line | 1 | 1999 | 2483 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1996 | 228 | 0.010 |
Why?
|
| Vitamins | 1 | 1993 | 92 | 0.010 |
Why?
|
| Receptors, Estrogen | 2 | 1984 | 430 | 0.010 |
Why?
|
| Melphalan | 2 | 1984 | 98 | 0.010 |
Why?
|
| Benz(a)Anthracenes | 1 | 1972 | 4 | 0.010 |
Why?
|
| Body Weight | 1 | 1993 | 456 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1972 | 53 | 0.010 |
Why?
|
| Paralysis | 1 | 1972 | 33 | 0.010 |
Why?
|
| Organophosphate Poisoning | 1 | 1971 | 2 | 0.010 |
Why?
|
| Poisoning | 1 | 1971 | 41 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1972 | 400 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1972 | 435 | 0.010 |
Why?
|
| Organ Size | 1 | 1972 | 370 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1993 | 817 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1990 | 195 | 0.000 |
Why?
|
| Postoperative Care | 2 | 1980 | 237 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1971 | 528 | 0.000 |
Why?
|
| Dacarbazine | 1 | 1987 | 104 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1987 | 229 | 0.000 |
Why?
|
| Vincristine | 1 | 1986 | 102 | 0.000 |
Why?
|
| Cyclohexenes | 1 | 1985 | 5 | 0.000 |
Why?
|
| Gastrointestinal Diseases | 1 | 1987 | 156 | 0.000 |
Why?
|
| Castration | 1 | 1985 | 32 | 0.000 |
Why?
|
| Multi-Institutional Systems | 1 | 1985 | 3 | 0.000 |
Why?
|
| Thermal Conductivity | 1 | 1985 | 4 | 0.000 |
Why?
|
| Stomach Ulcer | 1 | 1985 | 23 | 0.000 |
Why?
|
| Nausea | 1 | 1985 | 95 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1989 | 992 | 0.000 |
Why?
|
| Vomiting | 1 | 1985 | 109 | 0.000 |
Why?
|
| Body Temperature | 1 | 1985 | 128 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1985 | 215 | 0.000 |
Why?
|
| Mitoxantrone | 1 | 1984 | 65 | 0.000 |
Why?
|
| Child | 2 | 1987 | 7750 | 0.000 |
Why?
|
| Prednisolone | 1 | 1984 | 38 | 0.000 |
Why?
|
| Anemia | 1 | 1985 | 135 | 0.000 |
Why?
|
| Radiography | 1 | 1985 | 763 | 0.000 |
Why?
|
| Burns | 1 | 1985 | 150 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1983 | 20 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1985 | 158 | 0.000 |
Why?
|
| Pain Management | 1 | 1985 | 194 | 0.000 |
Why?
|
| Pain | 1 | 1985 | 417 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1983 | 420 | 0.000 |
Why?
|
| Cell Division | 1 | 1983 | 690 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1983 | 461 | 0.000 |
Why?
|
| Maxillary Neoplasms | 1 | 1980 | 7 | 0.000 |
Why?
|
| Hematuria | 1 | 1980 | 53 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1979 | 205 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1986 | 4042 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1980 | 418 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1983 | 826 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1986 | 2678 | 0.000 |
Why?
|